MSTN and chronic kidney disease: While our study focused on traditional lipid markers, incorporating apolipoproteins in future research could enhance the characterization of cardiovascular risk and deepen our understanding of the interplay between lipid metabolism, myostatin levels, and endothelial dysfunction in CKD populations.